Clinical trial
A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept
NCT02321241 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 1, 2016
- Completion date
- August 18, 2017
- Enrollment
- 236 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.